Skip to main content
Erschienen in: Infection 4/2022

22.03.2022 | COVID-19 | Review Zur Zeit gratis

SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis

verfasst von: Caterina Sagnelli, Margherita Macera, Clarissa Camaioni, Annabella Salvati, Nicola Coppola, Evangelista Sagnelli

Erschienen in: Infection | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

The COVID-19 pandemic significantly compromised screening, laboratory controls, clinical surveillance and treatment of chronic hepatitis patients and worsened their outcome, as evidenced by its significant correlation with advanced cirrhosis, liver decompensation and mortality.

Results

This pandemic significantly impaired also the sector of liver transplantation, whose wards, operating rooms, outpatients’ facilities, and healthcare personnel have been dedicated to patients with COVID-19. In addition, screening and treatment for HBV infection have been delayed or suspended in in most countries, with an increased risk of viral reactivation. Similar delay or suspension have also occurred for universal hepatitis B vaccination programs in many countries. Likewise, COVID-19 pandemic has made unreachable the goal of elimination of HCV infection as a worldwide public-health issue predicted for 2030 by the WHO.

Conclusion

This review article demonstrates how COVID-19 pandemic is causing serious damage to the sector of liver disease, which has quickly lost the beneficial effects of years of study, research, and clinical and technological application, as well as considerable financial investments.
Literatur
1.
Zurück zum Zitat Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2:100113.CrossRef Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2:100113.CrossRef
2.
Zurück zum Zitat Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020;40:1278–81.CrossRef Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020;40:1278–81.CrossRef
10.
Zurück zum Zitat Wang Q, Davis PB, Xu R. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. EClinicalMedicine. 2021;31:100688.CrossRef Wang Q, Davis PB, Xu R. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. EClinicalMedicine. 2021;31:100688.CrossRef
14.
Zurück zum Zitat Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasejeran R, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatology. 2020;73:705–8.CrossRef Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasejeran R, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatology. 2020;73:705–8.CrossRef
17.
Zurück zum Zitat Sarin SK, Choudhury A, Lau GK, et al. APASL COVID task force, APASL COVID liver injury spectrum study pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study; APASL COVID-19 liver injury spectrum study. Hepatol Int. 2020;14:690–700.CrossRef Sarin SK, Choudhury A, Lau GK, et al. APASL COVID task force, APASL COVID liver injury spectrum study pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study; APASL COVID-19 liver injury spectrum study. Hepatol Int. 2020;14:690–700.CrossRef
19.
Zurück zum Zitat Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US Multi-center Study. Clinical Gastroenetrology and Hepatology. 2021;19:1469-1479.e19.CrossRef Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US Multi-center Study. Clinical Gastroenetrology and Hepatology. 2021;19:1469-1479.e19.CrossRef
27.
Zurück zum Zitat Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159:768-771.e3.CrossRef Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159:768-771.e3.CrossRef
29.
Zurück zum Zitat Galiero R, Pafundi PC, Simeon V, Rinaldi L, Perrella A, Vetrano E, et al. Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: findings from COVOCA study. PLoS One. 2020;15:e0243700.CrossRef Galiero R, Pafundi PC, Simeon V, Rinaldi L, Perrella A, Vetrano E, et al. Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: findings from COVOCA study. PLoS One. 2020;15:e0243700.CrossRef
30.
Zurück zum Zitat Bajaj JS, Garcia-Tsao G, Biggins SW, Kamath PS, Wong F, McGeorge S, Shaw J, Pearson M, Chew M, Fagan A, de la Rosa RR, Worthington J, Olofson A, Weir V, Trisolini C, Dwyer S, Reddy KR. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2021;70:531–6. https://doi.org/10.1136/gutjnl-2020-322118.CrossRefPubMed Bajaj JS, Garcia-Tsao G, Biggins SW, Kamath PS, Wong F, McGeorge S, Shaw J, Pearson M, Chew M, Fagan A, de la Rosa RR, Worthington J, Olofson A, Weir V, Trisolini C, Dwyer S, Reddy KR. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2021;70:531–6. https://​doi.​org/​10.​1136/​gutjnl-2020-322118.CrossRefPubMed
32.
Zurück zum Zitat Su H-Y, Hsu Y-C, Su HY, Hsu YC. Patients with cirrhosis during the COVID-19 pandemic: current evidence and future perspectives. World J Clin Cases. 2021;9:2951–68.CrossRef Su H-Y, Hsu Y-C, Su HY, Hsu YC. Patients with cirrhosis during the COVID-19 pandemic: current evidence and future perspectives. World J Clin Cases. 2021;9:2951–68.CrossRef
36.
Zurück zum Zitat Domínguez-Gil B, Fernández-Ruiz M, Hernández D, Crespo M, Colmenero J, Coll E, Rubio JJ. Organ donation and transplantation during the COVID-19 pandemic: a summary of the Spanish Experience. Transplantation. 2021;105:29–36.CrossRef Domínguez-Gil B, Fernández-Ruiz M, Hernández D, Crespo M, Colmenero J, Coll E, Rubio JJ. Organ donation and transplantation during the COVID-19 pandemic: a summary of the Spanish Experience. Transplantation. 2021;105:29–36.CrossRef
39.
Zurück zum Zitat Rodríguez-Tajes S, Miralpeix A, Costa J, Lopez- Sune E, Laguno M, Pocurull A, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat. 2021;28:89–94.CrossRef Rodríguez-Tajes S, Miralpeix A, Costa J, Lopez- Sune E, Laguno M, Pocurull A, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat. 2021;28:89–94.CrossRef
41.
Zurück zum Zitat Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74:31–6.CrossRef Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74:31–6.CrossRef
42.
Zurück zum Zitat Buti M, Domínguez-Hernández R, Casado MA. Impact of the COVID-19 pandemic on HCV elimination in Spain. J Hepatol. 2021;74:1246–8.CrossRef Buti M, Domínguez-Hernández R, Casado MA. Impact of the COVID-19 pandemic on HCV elimination in Spain. J Hepatol. 2021;74:1246–8.CrossRef
46.
Zurück zum Zitat Balas EA, Jaffrey F, Kuperman GJ, Boren SA, Brown GD, Pinciroli F, Mitchell JA. Electronic communication with patients. Evaluation of distance medicine technology. JAMA. 1997;278:152–9.CrossRef Balas EA, Jaffrey F, Kuperman GJ, Boren SA, Brown GD, Pinciroli F, Mitchell JA. Electronic communication with patients. Evaluation of distance medicine technology. JAMA. 1997;278:152–9.CrossRef
47.
Zurück zum Zitat Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020;72:287–304. https://doi.org/10.1002/hep.31281.CrossRefPubMed Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020;72:287–304. https://​doi.​org/​10.​1002/​hep.​31281.CrossRefPubMed
50.
52.
Zurück zum Zitat Tian M, Wang B, Xue Z, Dong D, Liu X, Wu R, Yu L, Xiang J, Zhang X, Zhang X, Lv Y. Telemedicine for follow-up management of patients after liver transplantation: cohort study. JMIR Med Inform. 2021;9:e27175.CrossRef Tian M, Wang B, Xue Z, Dong D, Liu X, Wu R, Yu L, Xiang J, Zhang X, Zhang X, Lv Y. Telemedicine for follow-up management of patients after liver transplantation: cohort study. JMIR Med Inform. 2021;9:e27175.CrossRef
Metadaten
Titel
SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis
verfasst von
Caterina Sagnelli
Margherita Macera
Clarissa Camaioni
Annabella Salvati
Nicola Coppola
Evangelista Sagnelli
Publikationsdatum
22.03.2022
Verlag
Springer Berlin Heidelberg
Schlagwort
COVID-19
Erschienen in
Infection / Ausgabe 4/2022
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-022-01804-z

Weitere Artikel der Ausgabe 4/2022

Infection 4/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.